An AI healthcare ecosystem framework for Covid-19 detection and forecasting using CronaSona.

The primary purpose of this paper is to establish a healthcare ecosystem framework for COVID-19, CronaSona. Unlike some studies that focus solely on detection or forecasting, CronaSona aims to provide a holistic solution, for managing data and/or knowledge, incorporating detection, forecasting, expert advice, treatment recommendations, real-time tracking, and finally visualizing results. The innovation lies in creating a comprehensive healthcare ecosystem framework and an application that not only aids in COVID-19 diagnosis but also addresses broader health challenges. The main objective is to introduce a novel framework designed to simplify the development and construction of applications by standardizing essential components required for applications focused on addressing diseases. CronaSona includes two parts, which are stakeholders and shared components, and four subsystems: (1) the management information subsystem, (2) the expert subsystem, (3) the COVID-19 detection and forecasting subsystem, and (4) the mobile tracker subsystem. In the proposed framework, a CronaSona app. was built to try to put the virus under control. It is a reactive mobile application for all users, especially COVID-19 patients and doctors. It aims to provide a reliable diagnostic tool for COVID-19 using deep learning techniques, accelerating diagnosis and referral processes, and focuses on forecasting the transmission of COVID-19. It also includes a mobile tracker subsystem for monitoring potential carriers and minimizing the virus spread. It was built to compete with other applications and to help people face the COVID-19 virus. Upon receiving the proposed framework, an application was developed to validate and test the framework's functionalities. The main aim of the developed application, CronaSona app., is to develop and test a reliable diagnostic tool using deep learning techniques to avoid increasing the spread of the disease as much as possible and to accelerate the diagnosis and referral of patients by detecting COVID-19 features from their chest X-ray images. By using CronaSona, human health is saved and stress is reduced by knowing everything about the virus. It performs with the highest accuracy, F1-score, and precision, with consecutive values of 97%, 97.6%, and 96.6%.

An Assessment of Naturopathic Treatments, Health Concerns, and Common Comorbid Conditions in Fibromyalgia Patients: A Retrospective Medical Record Review.

Background: Fibromyalgia (FM) is characterized by chronic pain, with allodynia and hyperalgesia being the most common signs. Many patients with FM explore, express interest, and use complementary and alternative medicine to help manage symptoms and improve quality of life. However, little is known about the clinical recommendations provided by naturopathic doctors (NDs). Objective: To describe trends in assessment and treatment of patients with FM by NDs. Methods: Retrospectively, medical records of 200 patients with the FM ICD-10 code were reviewed from the Robert Schad Naturopathic Clinic. Of these records, 70 met inclusion criteria and were further analyzed. Comorbid conditions, health concerns, physical and psychological examinations, and treatment were recorded. Patients were excluded if informed consent for research was not signed. The project was approved by the Research Ethics Board of the Canadian College of Naturopathic Medicine. Results: Seventy patients met criteria and were included in the current analysis. Most patients identified as female (96%). Vitamin D (57%), magnesium (54%), omega-3 fish oil (53%), acupuncture by an acupuncturist (53%) or an ND (40%), B12 orally or by injection (40%), and probiotics (40%) were highly utilized treatments. A past/current medical history of digestive complaints (64%) and depression/mental illness (63%) were common comorbidities, alongside a history of arthritic conditions (53%) and anxiety (43%). A family history of arthritic conditions (47%) was also prevalent. The Widespread Pain Index and Symptom Severity tool (43%) was used to assess pain and other symptoms. No adverse effects of treatment were readily identifiable. Conclusion: Findings from this study reveal elements of both consistency and variability in the treatment recommendations from NDs in a teaching clinic environment. Future research that assesses or compares treatment recommendations for FM in other settings may be informative to better understand health services, the nature of individualized care, and patient experiences.

Elicitation of stakeholder viewpoints about medical cannabis research for pain management in critically ill ventilated patients: A Q-methodology study.

OBJECTIVES: To determine acceptability of medical cannabis research in critically ill patients. DESIGN: Q-methodology survey. SETTING: Convenience sample of healthcare providers and the general public were recruited at an acute care community hospital in Ontario, Canada. PARTICIPANTS: In the first phase, 63 respondents provided 197 unique viewpoints in response to a topic statement about medical cannabis use in critically ill patients. Twenty-five viewpoints were selected for the q-sample. In the second phase, 99 respondents ranked these viewpoints according to an a priori quasi normal distribution ranging from +4 (most agree) to -4 (least agree). Factor analysis was combined with comments provided by survey respondents to label and describe the extracted factors. RESULTS: The factor labels were hoping and caring (factor 1), pragmatic progress (factor 2), and cautious/conservative and protectionist (factor 3). Factor 1 describes a viewpoint of unequivocal support for medical cannabis research in this population with few caveats. Factor 2 describes a viewpoint of cautious support with a need to monitor for unintended adverse effects. Factor 3 describes a viewpoint of ensuring that current analgosedation techniques are optimized before exposing patients to another potentially harmful drug. CONCLUSIONS: Using a q-methodology design, we were able to sample and describe the viewpoints that exist about medical cannabis research in critically ill patients. Three factors emerged that seemed to adequately describe the relative ranking of q-statements by the majority of respondents. Combining the distinguishing statements along with respondent comments allowed us to determine that the majority support medical cannabis research in critically ill patients.

Does Integrative Medicine Reduce Prescribed Opioid Use for Chronic Pain? A Systematic Literature Review.

BACKGROUND: Chronic pain (CP) is a major public health problem. Many patients with CP are increasingly prescribed opioids, which has led to an opioid crisis. Integrative medicine (IM), which combines pharmacological and complementary and alternative medicine (CAM), has been proposed as an opioid alternative for CP treatment. Nevertheless, the role of CAM therapies in reducing opioid use remains unclear. OBJECTIVES: To explore the effectiveness of the IM approach or any of the CAM therapies to reduce or cease opioid use in CP patients. METHODS: An online search of MEDLINE and Embase, CINAHL, PubMed supp., and Allied and Complementary Medicine Database (AMED) for studies published in English from inception until February 15, 2018, was conducted. The Mixed Methods Appraisal Tool (MMAT) was used to critically appraise selected studies. RESULTS: The electronic search yielded 5,200 citations. Twenty-three studies were selected. Eight studies were randomized controlled trials, seven were retrospective studies, four studies were prospective observational, three were cross-sectional, and one was quasi-experimental. The majority of the studies showed that opioid use was reduced significantly after using IM. Cannabinoids were among the most commonly investigated approaches in reducing opioid use, followed by multidisciplinary approaches, cognitive-behavioral therapy, and acupuncture. The majority of the studies had limitations related to sample size, duration, and study design. CONCLUSIONS: There is a small but defined body of literature demonstrating positive preliminary evidence that the IM approach including CAM therapies can help in reducing opioid use. As the opioid crisis continues to grow, it is vital that clinicians and patients be adequately informed regarding the evidence and opportunities for IM/CAM therapies for CP.